Team

Team
Will Martinez
Founder & CEO
Will Martinez

Founder & CEO

The loss of dear family members and best friends to chronic diseases drew Will into the drug discovery industry and into solving major challenges to treat deadly diseases. Will, an immigrant from Peru, is very passionate about building excellent teams and relations with the most sophisticated drug discovery labs in the World. At Nanotech Bio, Will leads the formation of partnerships with leading pharma companies to enable the discovery of breakthrough medicines to battle deadly diseases. He has over 11 years of industrial experience in biosensor technology and manufacturing. He previously served in engineering roles at GE Global Research (GEGR) and Innovative Micro Technology (IMT). At IMT, Will was responsible for developing and manufacturing the first single-molecule DNA sequencing biosensor, which grew from zero to $10 million dollars in annual sales in less than 3 years. Will recognized a growing need in the drug discovery industry and the lack of biosystems to discover with vital emerging families of novel drug targets. Therefore, Nanotech Bio was born. Will received his Bachelor’s and Master’s degrees in Materials Engineering at the Colorado School of Mines and UCSB respectively. Will enjoys running and exploring the outdoors with his family during Holidays.

Jaime Arenas, PhD
Sr. Director, Science & Technology
Jaime Arenas, PhD

Sr. Director, Science & Technology

Jaime brings more than 25 years of experience translating biomolecular interactions into breakthrough technological advances for the life sciences industry. At Anadys Pharmaceuticals, Jaime developed a unique screening paradigm and established an antiviral drug discovery program for previously undruggable viral RNA targets. Later he focused on development of applications for cutting edge biosensor technologies. He led development of applications for the launch of the Flexchip, the first array-based surface plasmon resonance platform from Applied Biosystems. Jaime also invented the core biochemical approach for ultrasensitive biomarker assay products for BioScale’s acoustic MEMS platform. At TDK Headway technologies, he led Applications Development for single molecule detection using tunneling magnetoresistance (TMR) technology.
Jaime received his PhD in Biochemistry from the Albert Einstein College of Medicine and his postdoctoral training from the California Institute of Technology. On his free time, Jaime enjoys time with family, hiking, and cooking food recipes from all over the world.

Brian Wong, PhD
Director, Engineering
Brian Wong, PhD

Director, Engineering

Brian leads Nanotech Biomachines Engineering Team and brings a passion for developing innovative applications at the intersection of biology and micro-electrical-mechanical systems (MEMS). Prior to joining Nanotech Biomachines, he held a position as TD lithography process engineer at Intel’s Portland Technology Development (PTD), supporting multiple technology nodes and was part of the initial team demonstrating 7nm front end process. Brian is a founding member of GlucoSentient, a university startup focused on developing a library of antibody and DNA aptamer based Point of Care assays based on electrochemical detection of glucose.

Brian received his PhD in Materials Science and Engineering from University of Illinois, Urbana Champaign, under the guidance of Professor Yi Lu with a focus on functional DNA and nanoparticles for theragnostic applications.

Monica Lozano, PhD
Sr. Scientist, Assay Development
Monica Lozano, PhD

Sr. Scientist, Assay Development

Mónica brings 9+ years of industry and academic experience in the field of biophysics and cell membrane biology. In the Sensor Technology Group at Nanotech Bio, Mónica leads development of lipid membrane platforms for our graphene-based sensor for detection of ligand binding to native integral membrane proteins. She is responsible for kinetic binding assay development as well as transferring assays, instrumentation, and software to our customers. Prior to joining Nanotech Bio, Mónica was an Engineer and Scientific Communications Lead at Profusa where she helped bring non-dilutive funds from NIH and DARPA to develop a novel tissue-integrating biosensor.

Mónica holds a B.S. in Chemical Engineering from UC San Diego and obtained her Ph.D. in Chemical Engineering in the lab of Prof. Marjorie L. Longo at UC Davis, where she developed her passion for Lipid Membranes Science and its applications in biomedicine. She was a Ruth L. Kirschstein Postdoctoral Fellow in the lab of Prof. Steven Boxer in the Chemistry Department at Stanford University where she used the novel nanoSIMS mass spectrometry imaging tool to map the chemical composition of lipid membranes. In her free time, Monica enjoys reading and spending time with her family.

Venkata Manthina, PhD
Engineer, Process Development
Venkata Manthina, PhD

Engineer, Process Development

Venkata brings in 7 years of combined industrial and academic experience in semiconductor process development and device integration. He is responsible for process development and device engineering at Nanotech Bio and works closely with Brian Wong on the manufacture of graphene-based sensors.

Venkata received his PhD in Environmental Engineering from the University of Connecticut, Storrs where he led collaborative efforts for the development of low cost light emission devices. Later he was a Materials Engineer Postdoctoral Fellow at Fraunhofer USA where he developed low cost semiconductor materials for third generation solar cells, and ultra-low sensing gas sensors. Venkata enjoys reading, hiking and spending time with family.

Griselda Melendez
Research Associate, Assay Development
Griselda Melendez

Research Associate, Assay Development

Griselda’s responsibilities include biosensor qualification and assay development in the Sensor Technology Group. Prior to joining Nanotech Bio, Griselda was a Research Assistant at Texas Tech University Health Sciences Center where she performed research on characterization of single nucleotide polymorphisms (SNPs) associated with schizophrenia and bipolar disorder.
Griselda received her MS in Biological Sciences and her Bachelor’s in Microbiology at the University of Texas, El Paso. As a graduate Research Assistant she studied the interaction of the influenza virus with the cellular SUMOylation system and developed a novel method for detecting spliced mRNA through primer extension analysis with fluorescent primers.

In her free time, Griselda enjoys reading, photography, fishing and exploring the California coast.

Board
Michael Finney, PhD
Executive Board Director
Michael Finney, PhD

Executive Board Director

Dr. Finney received his BA degree in Biochemical Sciences from Harvard University and his Ph.D. in Biology from MIT. He was co-founder and CSO of MJ Research, which became one of the largest manufacturers of DNA amplification instruments. He was also a co-founder of MJ Bioworks, which along with MJ Research were sold to Bio-Rad (AMEX) in 2004. Since 2004, he has served as the Managing Director of Finney Capital, an investment firm based in San Francisco, and as a Board member in various life science companies. Dr. Finney was an early investor and Board Director at Wavemark, (acquired by Cardinal Health) and Innerscope Research (acquired by Nielsen). Mike has served on the Board of Directors of Nanotech Bio since April 2016, and he is also a hands-on advisor for business, technology, and strategic IP portfolio development. Dr. Finney also serves on the Board of Directors of Vaxart, Thrive Bioscience, Chimera Bioengineering, Orion Genomics, Sage Science, and SeqWell Inc. Dr. Finney is an author of 20 peer-reviewed publications and an inventor on 10 US patents.

Winnie Wan, PhD, MBA
Executive Board Director
Winnie Wan, PhD, MBA

Executive Board Director

Winnie Wan is a veteran in the bio-analytical industry, with extensive experience building and launching diagnostic and therapeutic businesses with start-ups and within large corporations. Winnie brings in over 32+ years of industrial experience, and she has successfully commercialized disruptive technologies from inception. These technologies include the analytical systems for drug discovery at ForteBio, Inc. (acquired by Pall Corporation), the anatomical pathology systems for cancer diagnosis at Becton Dickinson, the cell analysis systems at Guava Technologies, Inc. (acquired by Millipore Corporation), and the HIV drug model at SyStemix, Inc. (acquired by Novartis). She currently serves on the Board of Nanotech Bio, Bell Biosystems, and Aelan Cell Technologies, Inc. Previously, Dr. Wan held CEO/Board or Executive positions at OncoHealth Corp., BEING Biopharma, Inc., ForteBio, Inc., GeneTrol BioTherapeutics, Inc., Guava Technologies, Inc., Becton Dickinson’s CIS Division, and SyStemix, Inc. She received her Ph.D. in Biochemistry from Yale University, post-doctoral training in cell biology at Rockefeller University, and an M.B.A. from Columbia University.

Robert Leppo
Executive Board Director
Robert Leppo

Executive Board Director

Bob was the lead investor in Nanotech Bio when the company raised its Seed round. Bob has been active in the venture capital arena since 1983. He was an early investor in Advent Software (Acquired by SS&C for $2.63 billion) and ValueClick (acquired by Alliance Data Systems for $2.3 billion). Bob was also a lead investor in Best Internet acquired by Verio in 1999, OnPrem acquired by Copper Mountain in 2000, and Aero Astro, which was acquired by Radyne in 2007. In 1965 Bob earned his B.A. In History from Stanford University and went on to get his M.B.A. from Harvard Business School. Bob likes to read history, philosophy, practice physical fitness training.

Casey McGlynn
Corporate Attorney
Casey McGlynn

Corporate Attorney

Casey is a partner at Wilson Sonsini Goodrich & Rosati. Casey has been Nanotech Bio’s corporate attorney since 2015. Since joining WSGR in 1978, he has been a member of the firm's board of directors, and its Policy, Nominating, and Compensation Committees. Casey is a nationally recognized leader in the representation of start-up and growth technology companies, and is well known to an extensive network of angel investors, financiers, venture capitalists, corporate partners, and investment bankers. He has experience representing dozens of companies that have made successful initial public offerings and secondary offerings. Casey is a contributor to magazines and newsletters focused on angel and venture investing, and frequently speaks on issues relating to the organization and funding of new ventures.

Will Martinez
Founder & CEO
Will Martinez

Founder & CEO

The loss of dear family members and best friends to chronic diseases drew Will into the drug discovery industry and into solving major challenges to treat deadly diseases. Will, an immigrant from Peru, is very passionate about building excellent teams and relations with the most sophisticated drug discovery labs in the World. At Nanotech Bio, Will leads the formation of partnerships with leading pharma companies to enable the discovery of breakthrough medicines to battle deadly diseases. He has over 11 years of industrial experience in biosensor technology and manufacturing. He previously served in engineering roles at GE Global Research (GEGR) and Innovative Micro Technology (IMT). At IMT, Will was responsible for developing and manufacturing the first single-molecule DNA sequencing biosensor, which grew from zero to $10 million dollars in annual sales in less than 3 years. Will recognized a growing need in the drug discovery industry and the lack of biosystems to discover with vital emerging families of novel drug targets. Therefore, Nanotech Bio was born. Will received his Bachelor’s and Master’s degrees in Materials Engineering at the Colorado School of Mines and UCSB respectively. Will enjoys running and exploring the outdoors with his family during Holidays.

David Madden
CFO
David Madden

CFO

David has served as CFO of Nanotech Bio since 2017. David is a finance professional with over 30 years of experience covering all aspects of corporate finance for biotechnology, pharmaceutical, and life science companies. He has served as Chief Financial Officer for Alector LLC, AiroMedica LLC, Vaxart, Inc., XDx (now CareDx), and Arriva Pharmaceuticals. Previously, he was Associate Director of Corporate Finance for Chiron Corporation, which was acquired by Novartis. David received his B.A. in English from the University of California, Berkeley and his MBA in finance and international business from the University of Washington Michael G. Foster School of Business. He is Board member and treasurer of Can Do Multiple Sclerosis, which delivers educational programs for those with MS and their families, and of BioScience Forum, which conducts educational activities relating to the life sciences.

Advisors
Joe W. Gray, PhD
Professor & Chair, Department of Biomedical Engineering, Oregon Health and Science University
Joe W. Gray, PhD

Professor & Chair, Department of Biomedical Engineering, Oregon Health and Science University

Joe W. Gray, PhD is the Gordon Moore Endowed Chair, Biomedical Engineering; Director, Oregon Center for Spatial System Biomedicine (OCSSB) and Associate Director for Translational Research, Knight Cancer Institute at the Oregon Health and Science University. He is Principal Investigator of the National Cancer Institute / Integrative Cancer Biology Program (ICBP) Center for Cancer Systems Biology aimed at understanding and modeling of RTK signaling, Co-leader of a Stand Up to Cancer program aimed at rapidly improving management of the major subtypes of human breast cancer, PI of a DOD Innovator project aimed at improving early breast cancer detection and Co-investigator on human and mouse cancer genome atlas projects. Prof. Gray is a Scientific Advisor to Nanotech Biomachines, Inc. Dr. Gray's expertise is in molecular analysis technology, identification of genomic aberrations that contribute to cancer pathophysiology and development of systems biology strategies for enhanced marker guided cancer therapy – especially for breast and ovarian cancer. His work is described in more than 400 publications and in 70 US patents.

Marjorie Longo, PhD
Professor, Department of Chemical Engineering, University of California, Davis
Marjorie Longo, PhD

Professor, Department of Chemical Engineering, University of California, Davis

Marjorie is a Professor in the Department of Chemical Engineering at University of California, Davis and has performed research in the area of biological membranes for the past 28 years. She received her Ph.D. in Chemical Engineering from the University of California, Santa Barbara, and was a postdoctoral fellow at Cornell University School of Chemical Engineering, where she studied influenza virus membrane interactions. Marjorie received the College of Engineering Outstanding Mid-career Research Award and was a Joe and Essie Smith Endowed Chair and Chancellor's Fellow. She is a member of the Biophysical Society where she has served as a member of the Council, and Chair of the Membrane Structure and Assembly Subgroup. Her research has been funded by many agencies including NSF, DOE, USDA, and NIH and private foundations including the American Chemical Society, Petroleum Research Fund and the Whitaker Foundation. Marjorie has authored more than 100 research publications in the field of membrane biophysics.

Paul Schneir, PhD
Associate Professor, Institute for Neurodegenerative Diseases, UCSF School of Medicine
Paul Schneir, PhD

Associate Professor, Institute for Neurodegenerative Diseases, UCSF School of Medicine

Paul obtained his PhD in physical chemistry at UC Berkeley and a postdoctoral tenure at the Oak Ridge National Laboratory. Paul has extensive knowledge and experience in the field of drug discovery and biophysical methods for drug characterization. Paul has held leading roles in biophysical sciences in several pharmaceutical companies including Wyeth, Amgen, and Genentech. Paul’s current research is on drug discovery of new drugs for neurodegenerative diseases. Paul’s experience brings deep understanding of the pharmaceutical drug discovery process to align Nanotech Bio’s application with the market needs.